| Ankylosing spondylitis
Hulio vs Rinvoq
Side-by-side clinical, coverage, and cost comparison for ankylosing spondylitis.Deep comparison between: Hulio vs Rinvoq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRinvoq has a higher rate of injection site reactions vs Hulio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rinvoq but not Hulio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hulio
Rinvoq
At A Glance
SC injection
Every 1-2 weeks
TNF-alpha inhibitor
Oral
Once daily or twice daily (pediatric oral solution)
JAK inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Dermatitis, Atopic
- Ulcerative Colitis
- Crohn Disease
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Juvenile polyarthritis
- Giant Cell Arteritis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some Rheumatoid Arthritis patients not taking concomitant MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile arthritis Patients 2 years of age and older: 15 kg to <30 kg: 20 mg SC every other week; >=30 kg: 40 mg SC every other week.
Crohn Disease Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years weighing 17 kg to <40 kg: 80 mg Day 1, 40 mg Day 15, 20 mg every other week; weighing >=40 kg: 160 mg Day 1, 80 mg Day 15, 40 mg every other week.
Ulcerative Colitis 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis vulgaris, Uveitis 80 mg SC initial dose, followed by 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Rheumatoid Arthritis 15 mg orally once daily
Arthritis, Psoriatic - Adults 15 mg orally once daily
Arthritis, Psoriatic - Pediatric 2 to <18 years Dosing based on weight: 10-<20 kg: 3 mg oral solution twice daily; 20-<30 kg: 4 mg oral solution twice daily; >=30 kg: 6 mg oral solution twice daily or 15 mg tablet once daily
Dermatitis, Atopic - Adults <65 years 15 mg orally once daily; may increase to 30 mg once daily if inadequate response
Dermatitis, Atopic - Adults >=65 years 15 mg orally once daily
Ulcerative Colitis - Induction 45 mg orally once daily for 8 weeks
Ulcerative Colitis - Maintenance 15 mg orally once daily; may use 30 mg once daily for refractory, severe, or extensive disease
Crohn Disease - Induction 45 mg orally once daily for 12 weeks
Crohn Disease - Maintenance 15 mg orally once daily; may use 30 mg once daily for refractory, severe, or extensive disease
Ankylosing spondylitis 15 mg orally once daily
Non-Radiographic Axial Spondyloarthritis 15 mg orally once daily
Juvenile polyarthritis Dosing based on weight: 10-<20 kg: 3 mg oral solution twice daily; 20-<30 kg: 4 mg oral solution twice daily; >=30 kg: 6 mg oral solution twice daily or 15 mg tablet once daily
Giant Cell Arteritis 15 mg orally once daily in combination with tapering corticosteroids; may continue as monotherapy after corticosteroid discontinuation
Contraindications
—
- Known hypersensitivity to upadacitinib or any excipients
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, accidental injury, urinary tract infection, abdominal pain, flu syndrome, hyperlipidemia, back pain, hypercholesterolemia, hypertension, hematuria, alkaline phosphatase increased.
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, hepatitis B virus reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity, severe hepatic reactions including acute liver failure.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, pyrexia, liver failure, hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, lichenoid skin reaction, systemic vasculitis, deep vein thrombosis.
Most common (>=3%) - Rheumatoid Arthritis Upper respiratory tract infection, nausea, cough, pyrexia
Most common (>=3%) - Atopic Dermatitis Upper respiratory tract infection, acne, herpes simplex, headache, increased blood creatine phosphokinase, cough, hypersensitivity, folliculitis, nausea, abdominal pain
Most common (>=3%) - Ulcerative Colitis Induction Upper respiratory tract infection, acne, increased blood creatine phosphokinase, neutropenia, rash, elevated liver enzymes, lymphopenia
Most common (>=3%) - Ulcerative Colitis Maintenance Upper respiratory tract infection, increased blood creatine phosphokinase, pyrexia, neutropenia, elevated liver enzymes, rash, herpes zoster, folliculitis, hypercholesterolemia, influenza, herpes simplex
Most common (>=3%) - Crohn Disease Induction Upper respiratory tract infection, anemia, acne, pyrexia, increased blood creatine phosphokinase, influenza, herpes simplex
Most common (>=3%) - Crohn Disease Maintenance Upper respiratory tract infection, pyrexia, herpes zoster, headache, acne, gastroenteritis, fatigue, increased blood creatine phosphokinase
Most common (>=5%) - Giant Cell Arteritis Upper respiratory tract infection, headache, fatigue, peripheral edema, cough, anemia, rash, herpes zoster, nausea
Serious Serious infections, opportunistic infections, tuberculosis, malignancies, major adverse cardiovascular events, thrombosis, gastrointestinal perforations, hypersensitivity reactions, eczema herpeticum
Pharmacology
Adalimumab-fkjp is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, reducing inflammatory and immune responses in conditions including RA, JIA, PsA, AS, CD, UC, Ps, HS, and UV.
Upadacitinib is a JAK inhibitor that modulates intracellular signaling by preventing JAK-mediated phosphorylation and activation of STATs, thereby influencing immune cell function and hematopoiesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hulio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Rinvoq
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Hulio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rinvoq
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (8/8)
Humana
Hulio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Rinvoq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hulio.
Cost estimate not availableCo-Pay Relief Rheumatoid Arthritis Fund
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.